A study of 3 lots of an investigational vaccine against respiratory syncytial virus (RSV) in adults aged 60 years and above

Trial Identifier: 217131
Sponsor: GlaxoSmithKline
Start Date: October 2021
Primary Completion Date: January 2022
Study Completion Date: June 2022
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, British Columbia Vancouver, British Columbia, Canada, V5Z 1K3
Canada, New Brunswick Moncton, New Brunswick, Canada, E1G1A7
Canada, Nova Scotia Truro, Nova Scotia, Canada, B2N 1L2
Canada, Ontario Toronto, Ontario, Canada, M3J 2C5
Canada, Québec Quebec, Québec, Canada, G1W 4R4
Canada, Québec Sherbrooke, Québec, Canada, J1J 2G2
Canada, Québec St-Charles-Borromée, Québec, Canada, J6E 2B4
Sweden ESKILSTUNA, Sweden, SE-631 88
Sweden KARLSKRONA, Sweden, SE-371 79
Sweden UPPSALA, Sweden, SE-752 37
United States, Connecticut Waterbury, Connecticut, United States, 06708
United States, Florida Brooksville, Florida, United States, 34613
United States, Florida Immokalee, Florida, United States, 34142
United States, Georgia Buford, Georgia, United States, 30519
United States, Minnesota Minneapolis, Minnesota, United States, 55402
United States, Mississippi Petal, Mississippi, United States, 39465
United States, Nebraska Omaha, Nebraska, United States, 68144
United States, North Carolina Greensboro, North Carolina, United States, 27408
United States, Texas Houston, Texas, United States, 77058